|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui
R and Zhang X: Circulating MicroRNAs in Cancer: Potential and
Challenge. Front Genet. 10:6262019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirales Casillas CE, Flores Fernández JM,
Padilla Camberos E, Herrera López EJ, Leal Pacheco G and Martínez
Velázquez M: Current status of circulating protein biomarkers to
aid the early detection of lung cancer. Future Oncol. 10:1501–1513.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu W, Chang J, Du X and Hou J: Long
non-coding RNA PCAT-1 contributes to tumorigenesis by regulating
FSCN1 via miR-145-5p in prostate cancer. Biomed Pharmacother.
95:1112–1118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Wen X, Hu XL, Cheng LZ, Yu JY and
Wei ZB: Downregulation of miR-145-5p correlates with poor prognosis
in gastric cancer. Eur Rev Med Pharmacol Sci. 20:3026–3030.
2016.PubMed/NCBI
|
|
7
|
Chang Y, Yan W, Sun C, Liu Q, Wang J and
Wang M: miR-145-5p inhibits epithelial-mesenchymal transition via
the JNK signaling pathway by targeting MAP3K1 in non-small cell
lung cancer cells. Oncol Lett. 14:6923–6928. 2017.PubMed/NCBI
|
|
8
|
Wang M, Wang J, Deng J, Li X, Long W and
Chang Y: MiR-145 acts as a metastasis suppressor by targeting
metadherin in lung cancer. Med Oncol. 32:3442015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kieran MW, Kalluri R and Cho YJ: The VEGF
pathway in cancer and disease: Responses, resistance, and the path
forward. Cold Spring Harb Perspect Med. 2:a0065932012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ,
Jiang Y, Chen X, Qi Y, Zhang X, et al: MiR-145 inhibits tumor
angiogenesis and growth by N-RAS and VEGF. Cell Cycle.
11:2137–2145. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaniad P, Trakunran K, Geater SL,
Keeratichananont W, Thongsuksai P and Raungrut P: Serum miRNAs
associated with tumor-promoting cytokines in non-small cell lung
cancer. PLoS One. 15:e02415932020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Ta WW, Sun PF, Meng YF and Zhao
CZ: Diagnostic and prognostic significance of serum miR-145-5p
expression in glioblastoma. Int J Clin Exp Pathol. 12:2536–2543.
2019.PubMed/NCBI
|
|
13
|
Liang H, Jiang Z, Xie G and Lu Y: Serum
microRNA-145 as a novel biomarker in human ovarian cancer. Tumour
Biol. 36:5305–5313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Komatsu H, Oishi T, Itamochi H, Shimada M,
Sato S, Chikumi J, Sato S, Nonaka M, Sawada M, Wakahara M, et al:
Serum vascular endothelial growth factor-A as a prognostic
biomarker for epithelial ovarian cancer. Int J Gynecol Cancer.
27:1325–1332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang RJ, Zheng YH, Wang P and Zhang JZ:
Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in
non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771.
2015.PubMed/NCBI
|
|
16
|
Chakra M, Pujol JL, Lamy PJ, Bozonnat MC,
Quantin X, Jacot W and Daurès JP: Circulating serum vascular
endothelial growth factor is not a prognostic factor of non-small
cell lung cancer. J Thorac Oncol. 3:1119–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen H, Shen J, Wang L, Shi Z, Wang M,
Jiang BH and Shu Y: Low miR-145 expression level is associated with
poor pathological differentiation and poor prognosis in non-small
cell lung cancer. Biomed Pharmacother. 69:301–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akın Kabalak P, Çiledağ A, Demir N, Çelik
G, Yüksel C, Köycü G, Gökmen Öztuna D, Taner A, Kaya A, Kutlay H,
et al: Prognostic significance of serum vascular endothelial growth
factor and Angiopoietin-2 in patients with lung cancer. Tuberk
Toraks. 63:71–77. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bossuyt PM: Clinical validity: Defining
biomarker performance. Scand J Clin Lab Invest Suppl. 242:46–52.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trakunram K, Chaniad P, Geater SL,
Keeratichananont W, Chittithavorn V, Uttayamakul S, Buya S,
Raungrut P and Thongsuksai P: Serum miR-339-3p as a potential
diagnostic marker for non-small cell lung cancer. Cancer Biol Med.
17:652–663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al WHO Panel, : The 2015 World Health Organization
Classification of Lung Tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao X, Huang X, Zhou Z and Lin X: An
improvement of the 2ˆ(−delta delta CT) method for quantitative
real-time polymerase chain reaction data analysis. Biostat
Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li S, Wang L, Meng Y, Chang Y, Xu J and
Zhang Q: Increased levels of LAPTM4B, VEGF and survivin are
correlated with tumor progression and poor prognosis in breast
cancer patients. Oncotarget. 8:41282–41293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang L, Hochwald S, Deng S, Chen Y, Tan
C, Zhong Q and Huang H: Diagnostic and prognostic performance of
serum vascular endothelial growth factor, vascular endothelial
growth factor receptor 2, and osteopontin for gastrointestinal
cancers. Clin Lab. 65:652019. View Article : Google Scholar
|
|
27
|
Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu
W, Hao KK, Xu CH and Qian Q: Prognostic values of VEGF and
endostatin with malignant pleural effusions in patients with lung
cancer. Asian Pac J Cancer Prev. 15:8435–8440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wozniak MB, Scelo G, Muller DC, Mukeria A,
Zaridze D and Brennan P: Circulating microRNAs as non-invasive
biomarkers for early detection of non-small-cell lung cancer. PLoS
One. 10:e01250262015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimanuki Y, Takahashi K, Cui R, Hori S,
Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular
endothelial growth factor in the prediction of angiogenesis and
prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zeinali T, Karimi L, Hosseinahli N,
Shanehbandi D, Mansoori B, Mohammadi A, Hajiasgharzadeh K, Babaloo
Z, Majidi-Zolbanin J and Baradaran B: Overexpression of miRNA-145
induces apoptosis and prevents proliferation and migration of
MKN-45 gastric cancer cells. EXCLI J. 19:1446–1458. 2020.PubMed/NCBI
|
|
31
|
Ding W, Tan H, Zhao C, Li X, Li Z, Jiang
C, Zhang Y and Wang L: MiR-145 suppresses cell proliferation and
motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour
Biol. 37:6255–6260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan Y, Ye C, Tian Q, Yan S, Zeng X, Xiao
C, Wang L and Wang H: miR-145 suppresses the proliferation,
invasion and migration of NSCLC cells by regulating the BAX/BCL-2
ratio and the caspase-3 cascade. Oncol Lett. 15:4337–4343.
2018.PubMed/NCBI
|
|
33
|
Ye Z, Shen N, Weng Y, Li K, Hu L, Liao H,
An J, Liu L, Lao S and Cai S: Low miR-145 silenced by DNA
methylation promotes NSCLC cell proliferation, migration and
invasion by targeting mucin 1. Cancer Biol Ther. 16:1071–1079.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng
A and Hu J: miRNA-145 inhibits non-small cell lung cancer cell
proliferation by targeting c-Myc. J Exp Clin Cancer Res.
29:1512010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan L, Wu Q, Xing X, Wei Y and Shao Z:
MicroRNA-145 targets vascular endothelial growth factor and
inhibits invasion and metastasis of osteosarcoma cells. Acta
Biochim Biophys Sin (Shanghai). 44:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li YQ, He QM, Ren XY, Tang XR, Xu YF, Wen
X, Yang XJ, Ma J and Liu N: MiR-145 inhibits metastasis by
targeting fascin actin-bundling protein 1 in nasopharyngeal
carcinoma. PLoS One. 10:e01222282015. View Article : Google Scholar : PubMed/NCBI
|
